The article offers information on GlaxoSmithKline and the PATH Malaria Vaccine Initiative (MVI) releasing data from trial of the malaria vaccine. It states that the vaccine shows mediocre efficacy whose effect declines over time. It mentions that it might become the first malaria vaccine to receive regulatory approval.